Is it safer CARs that we need, or safer rules of the road?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer.Molecular therapy oncolytics · 2021
   Article
2. Genetically enhanced T lymphocytes and the intensive care unit.Oncotarget · 2018
   Review
3. Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Protein & cell · 2017
   Review
4. The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.Cancer gene therapy · 2017
   Article
5. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012
   Article
6. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.Human gene therapy · 2012
   Article

Corrections and comments

• Comment on
  Safer CARS.2010

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as